TY - JOUR
T1 - Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors
AU - Takahashi, Yu
AU - Akishima-Fukasawa, Yuri
AU - Kobayashi, Noritoshi
AU - Sano, Tsuyoshi
AU - Kosuge, Tomoo
AU - Nimura, Yuji
AU - Kanai, Yae
AU - Hiraoka, Nobuyoshi
PY - 2007/1/1
Y1 - 2007/1/1
N2 - Purpose: It is difficult to predict the biological behavior of pancreatic endocrine tumors (PETs). Our aim was to evaluate the prognostic significance of certain variables in PETs. Experimental Design: The following variables were examined in 37 patients with PETs and then compared with other clinicopathologic characteristics: histologic tumor structure; microvessel density (MVD) measured by three different methods, including a unique method involving calculation of solid area MVD; endothelial proliferation; and the immunohistochemical expression of vascular endothelial growth factor-A and CXC chemokine CXCL-12. lntratumoral vascular structures were analyzed by double immunofluorescence using 30-μm-thick sections. Results: The presence of focal and intensive solid growth of tumor cells (large solid nests; P = 0.003), low solid area MVD (P = 0.002), a high endothelial cell proliferation index (EPI; P = 0.005). and high expression of CXCL-12 in PETcells (P = 0.018) were significant unfavorable prognostic indicators. The predominant structure of the overall tumor histology and the expression of vascular endothelial growth factor-A did not separate aggressive PETs. In areas of focal solid growth, tumor-associated blood vessels had obviously low MVD and high EPI, and their structures were poorly formed with highly abnormal features, in comparison with other areas. High expression of CXCL-12 in tumor cells was significantly associated with variables representing tumor growth, hematogenous tumor spread, low MVD, high EPI, and the presence of large solid nests. Conclusions: This study has provided novel findings on the prognostic features of tumor architecture and tumor-associated angiogenesis in PETs. CXCL-12 is the first candidate molecule in association with neoangiogenesis in PETs.
AB - Purpose: It is difficult to predict the biological behavior of pancreatic endocrine tumors (PETs). Our aim was to evaluate the prognostic significance of certain variables in PETs. Experimental Design: The following variables were examined in 37 patients with PETs and then compared with other clinicopathologic characteristics: histologic tumor structure; microvessel density (MVD) measured by three different methods, including a unique method involving calculation of solid area MVD; endothelial proliferation; and the immunohistochemical expression of vascular endothelial growth factor-A and CXC chemokine CXCL-12. lntratumoral vascular structures were analyzed by double immunofluorescence using 30-μm-thick sections. Results: The presence of focal and intensive solid growth of tumor cells (large solid nests; P = 0.003), low solid area MVD (P = 0.002), a high endothelial cell proliferation index (EPI; P = 0.005). and high expression of CXCL-12 in PETcells (P = 0.018) were significant unfavorable prognostic indicators. The predominant structure of the overall tumor histology and the expression of vascular endothelial growth factor-A did not separate aggressive PETs. In areas of focal solid growth, tumor-associated blood vessels had obviously low MVD and high EPI, and their structures were poorly formed with highly abnormal features, in comparison with other areas. High expression of CXCL-12 in tumor cells was significantly associated with variables representing tumor growth, hematogenous tumor spread, low MVD, high EPI, and the presence of large solid nests. Conclusions: This study has provided novel findings on the prognostic features of tumor architecture and tumor-associated angiogenesis in PETs. CXCL-12 is the first candidate molecule in association with neoangiogenesis in PETs.
UR - http://www.scopus.com/inward/record.url?scp=33846325502&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33846325502&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-06-1408
DO - 10.1158/1078-0432.CCR-06-1408
M3 - Article
C2 - 17200354
AN - SCOPUS:33846325502
SN - 1078-0432
VL - 13
SP - 187
EP - 196
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 1
ER -